Hisamitsu's transdermal oxybutynin set for Phase III
This article was originally published in Scrip
Executive Summary
Hisamitsu is planning to take a transdermal formulation of the muscarinic antagonist oxybutynin hydrochloride (HOB-294) into Phase III development for overactive bladder symptoms following positive results in a Japanese trial.